Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
Sign in with Google
bearish
Akeso Biopharma Inc
Watchlist
Akeso Biopharma Inc (9926.HK) - Caution Is Advised Until Sufficient Financing Is Secured
Equity Bottom-Up
323 Views
28 Mar 2022 00:59
Akeso has a high starting point, with strong R&D capability and valuable pipeline. However, related clinical trials will drain money fast. So, caution is advised until sufficient financing is secured.
SUMMARY
(Sign Up to Access)
Full Insight
(Paid Plans Only, 4-minute read)
Related Insights
More »
Loading
Trending Collections
More »
Index Rebalance
Equity Bottom-Up
Event-Driven
South Korea
Japan
Equity Derivatives
Podcasts
Equity Capital Markets (ECM)
Unpaywalled Insights
India
Trending Insights
More »
[Japan Activism] ISS Comes Out Supporting Orbis Against Tsuruha/Welcia Merger Ratio
GMO Internet (4784) Offering - This Is a GINORMOUS Re-IPO - AVOID LIKE THE PLAGUE
POSCO Future M: A Rights Offering Capital Raise of 1.1 Trillion Won
Hang Seng Index (HSI) Rebalance Preview: Inclusion Candidates for June25
Frasers Hospitality Trust (FHT SP): Frasers Property & TCC Reload Scheme
Top Unpaywalled Insights
More »
AQR DNA in a Digital World: Systematic Edge with Connor Farley - The New Barbarians Episode #019
Curator's Cut: "Bubble" Tea, Japan M&A 🍿and TSMC from Different Lenses
The Coming Global Trade Re-Ordering
The Polycrisis Era (2025–2028): Navigating a World of Overlapping Disruptions
Our AI-Powered Accounting Risk Trading Strategy Beat the S&P 500 by 2.5x
Discussions
(Paid Plans Only)
Price Chart
(Sign Up to Access)
Insight Stream
Pre-IPO Betters Medical Investment Holdings - The Industry, the Business and the Concerns
05 May 2022
China Healthcare Weekly (Apr.1)- Lower Budget of Public Hospitals, IPO Environment, Impatient Market
03 Apr 2022
Pre-IPO Guanze Intelligent Medical Information Industry - Advantages in Shandong Cannot Hide Worries
01 Apr 2022
Akeso Biopharma Inc (9926.HK) - Caution Is Advised Until Sufficient Financing Is Secured
28 Mar 2022
The Impact of HFCAA on China ADR (China Healthcare Companies)
16 Mar 2022
Jiangsu Hengrui Medicine (600276.CH) - Here’s when Hengrui May Recover
14 Mar 2022
BeiGene Ltd (6160.HK/688235.CH) - There Is No Way to Retreat
08 Mar 2022
Top
For Institutional Investors and Financial Services
For Corporate IR and Strategy
For Private Wealth Intermediaries
Pricing
Who We Are
Careers
FAQs
Research Provider Solutions
Syndicate your Publications
Compliance
Terms of Use
Privacy Policy
Press Kit
RSS Feeds
Request a Free Trial
Avail a Transition Account
Guest Posts on Smartkarma
Other Enquiries
Join TL;DR Community
Free Weekly Newsletters
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.53.3
x